Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Glivec (imatinib) and nilotinib in aggressive fibromatosis / desmoid tumors
2007-000624-40Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and nilotinib in aggressive fibromatosis (AF) (2 arms), sponsored by Heidelberg University. Primary endpoint: Non-progression rate at 6 months. Started Mar 2010; status: completed.
02
Drugs
imatinibnilotinib
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on 2007-000624-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000624-40.